1,070,000

$ 618,000

Original annual targets percentage

73.50%

Incurred Board fees total

$ 82,500

$ 247,500

$ 240,000

Annual base salary

$ 183,750

$ 175,000

Annual base salary

$ 469,000

$ 348,000

Issuance of unsecured notes, description

the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 19, 2022	Dec. 15, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
IfrsStatementLineItems [Line Items]
Portage ordinary shares						1,070,000
Loss from change increase in the fair value of the liability				$ 4,580,000		$ 4,126,000
Annual base salary			$ 618,000
Compensation committee	$ 600,000
Original annual targets percentage	73.50%
Accounts payable and accrued expenses				400,000		400,000		$ 400,000
Incurred Board fees total				$ 82,500	$ 82,500	$ 247,500	$ 240,000
Annual fees description						Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committee of the Board is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees are entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.
Bottom of range [member]
IfrsStatementLineItems [Line Items]
Annual base salary		$ 183,750	$ 175,000
Annual bonus targets ranging percentage		30.00%	30.00%
Top of range [member]
IfrsStatementLineItems [Line Items]
Annual base salary		$ 469,000	$ 348,000
Annual bonus targets ranging percentage		40.00%	40.00%
Salva Rx [Member]
IfrsStatementLineItems [Line Items]
Issuance of unsecured notes, description						the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.